Mucoadhesive chitosan-clotrimazole hydrogel for enhanced candidiasis treatment
A novel mucoadhesive chitosan-clotrimazole hydrogel enhances treatment efficacy for vaginal candidiasis by improving drug residence time and synergizing antifungal activity. The hydrogel rapidly gels at body temperature and is designed for once-a-day application.
Overview
The mucoadhesive chitosan-clotrimazole hydrogel is a cutting-edge solution for treating vaginal candidiasis, commonly known as yeast infections. This innovative hydrogel combines chitosan, a natural polysaccharide, with the antifungal drug clotrimazole to enhance treatment efficacy. The hydrogel offers a rapid gelation rate at body temperature and significantly increased mechanical resistance compared to conventional chitosan hydrogels. Its unique mucoadhesive properties ensure prolonged residence time of clotrimazole at the infection site, allowing for effective once-a-day treatment. The hydrogel acts synergistically with clotrimazole, enhancing antifungal activity and potentially mitigating drug resistance.
Technical specifications
- Rapid Gelation: The hydrogel quickly transitions to a gel state at 37°C, facilitating easy application.
- Enhanced Mechanical Resistance: Up to 37-fold increase in Young’s modulus post-gelation.
- Mucoadhesion: Positively charged amino groups interact with mucosa, forming hydrogen bonds with mucin glycoproteins for strong adhesion.
- Therapeutic Delivery: Sustains therapeutic levels of clotrimazole at the infection site.
- Antifungal Synergy: Disrupts fungal cell walls and enhances cell permeability, leading to improved efficacy and reduced resistance.
- Formulation Flexibility: Potential for delivery in various forms such as creams, foams, or sprays.
Technology readiness level
The technology is currently at TRL 4, indicating that it has been validated in laboratory settings. Ongoing efforts focus on optimizing the hydrogel's composition, characterizing its properties, and evaluating its efficacy in small animal models compared to clotrimazole alone.
About Chitolytic
ChitoLytic is a biotechnology company that manufactures and supplies high-purity, high-quality chitosan derived from crustacean shells and non-animal, vegetal sources. The company utilizes proprietary clean-tech enzymatic processes and patented non-thermal atmospheric pressure nitrogen plasma technology to decontaminate its chitosan. This plasma-treatment innovation is critical, as it eliminates impurities, pyrogens, and endotoxins without the damaging effects of traditional sterilization methods like harsh chemicals or irradiation, enabling the material to meet the rigorous standards required for advanced biomedical, pharmaceutical, and medical device applications.
By providing medical-grade, sterile, and endotoxin-free chitosan, ChitoLytic enables researchers and manufacturers to leverage the biopolymer's natural properties—such as biocompatibility, antimicrobial activity, and hemostatic capabilities—in sensitive areas including drug delivery vehicles, tissue engineering scaffolds, and implantable medical devices. Beyond high-end biomedical use, the company supports a broad spectrum of sectors, offering mid-grade and industrial-grade chitosan for applications in nutraceuticals, cosmetics, agriculture, food preservation, and water treatment. The company, which originated from research collaborations at Memorial University, serves a global customer base from its headquarters in Toronto, Canada.
delivered to your inbox.